Phase II open label, multi-center clinical trial of modulation of intermediate endpoint biomarkers by 1a-hydroxyvitamin D2 in patients with clinically localized prostate cancer and high grade pin.

Phase II open label, multi-center clinical trial of modulation of intermediate endpoint biomarkers by 1a-hydroxyvitamin D2 in patients with clinically localized prostate cancer and high grade pin. Prostate. 2013 Jun; 73(9):970-8.

View in: PubMed

subject areas

Biomarkers, Tumor
Endpoint Determination
Ergocalciferols
Fibroblast Growth Factor 2
Humans
Insulin-Like Growth Factor Binding Protein 3
Insulin-Like Growth Factor I
Kallikreins
Male
Microvessels
Middle Aged
Placebos
Prostatectomy
Prostate-Specific Antigen
Prostatic Neoplasms
Transforming Growth Factor beta1
Transforming Growth Factor beta2
Vascular Endothelial Growth Factor A
Vitamin D

authors with profiles

GEORGE WILDING